Radium Ra 223 dichloride is under clinical development by Bayer and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Radium Ra 223 dichloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Radium Ra 223 dichloride overview

Radium-223 chloride (Xofigo) is an antineoplastic agent, It is formulated as solution for intravenous route of administration. It is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.

Radium-223 chloride is under development for the treatment of castration resistant prostate cancer (CRPC) with bone metastasis, with bone metastases, metastatic renal cell carcinoma and metastatic osteosarcoma. It was also under development for the treatment of non-small cell lung cancer (NSCLC), metastatic castration-resistant (hormone-refractory) prostate cancer and metastatic HER2 negative hormone receptor-positive breast cancer patients with bone metastases and multiple myeloma.

Bayer overview

Bayer (Bayer) is engaged in the discovery, development, manufacturing, and commercialization of products for human health, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology, and other indications. It also strives to develop new molecules and technologies for use in the fields of medicine and modern agriculture. The company’s product portfolio includes prescription products, specialty pharmaceuticals, diagnostic imaging equipment, non-prescription (over the counter or OTC) products, seeds, crop protection solutions and non-agricultural pest control solutions. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals, and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa, and the Middle East. Bayer is headquartered in Leverkusen, North Rhine-Westphalia, Germany.

For a complete picture of Radium Ra 223 dichloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.